Caris Life Sciences (CAI) Non Operating Income (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Non Operating Income of -$5.9 million for Q1 2026, up 86.72% year-over-year from -$3.2 million in Q1 2025, and up 8.18% quarter-over-quarter from -$6.5 million in Q4 2025.
Caris Life Sciences (CAI) Non Operating Income (2024 - 2026) Analysis & Trends
Caris Life Sciences' Non Operating Income history runs 3 years deep, the most recent figure standing at -$5.9 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 86.72% year-over-year to -$5.9 million; the TTM figure through Mar 2026 stood at -$74.5 million (down 47.25% YoY), while the FY2025 annual figure was -$113.2 million, down 357.05% from the prior year.
- Non Operating Income for Q1 2026 stood at -$5.9 million, up from -$6.5 million in the prior quarter.
- The five-year high for Non Operating Income was $825000.0 in Q2 2024, with the low at -$53.8 million in Q2 2025.
- The 3-year median for Non Operating Income is -$6.7 million (2024), against an average of -$15.6 million.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income tumbled 6621.33% in 2025, then surged 86.72% in 2026.
- Caris Life Sciences' Non Operating Income stood at $99000.0 in 2024, then sank by 6619.19% to -$6.5 million in 2025, then grew by 8.18% to -$5.9 million in 2026.
- Business Quant data shows CAI's Non Operating Income at -$5.9 million in Q1 2026, -$6.5 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | -27.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.54 Mn |
| Mar 31, 2026 | -5.93 Mn |
| Dec 31, 2025 | -6.45 Mn |
| Sep 30, 2025 | -8.32 Mn |
| Jun 30, 2025 | -53.80 Mn |
| Mar 31, 2025 | -44.63 Mn |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | -6.89 Mn |
| Jun 30, 2024 | 825,000.00 |